Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

dc.contributor.authorÖrmeci, Necati
dc.contributor.departmentTıp Fakültesitr_TR
dc.date.accessioned2021-01-05T07:36:22Z
dc.date.available2021-01-05T07:36:22Z
dc.date.issued2018
dc.description.abstractThis consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.tr_TR
dc.description.indexPubmed
dc.identifier.endpage269tr_TR
dc.identifier.issue3tr_TR
dc.identifier.startpage259tr_TR
dc.identifier.urihttps://doi.org/10.5152/tjg.2018.18263tr_TR
dc.identifier.urihttp://hdl.handle.net/20.500.12575/72622
dc.identifier.volume29tr_TR
dc.language.isoentr_TR
dc.relation.isversionof10.5152/tjg.2018.18263tr_TR
dc.relation.journalTurk J Gastroenterol .tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıtr_TR
dc.subjectHepatitis Btr_TR
dc.subjectimmunosuppressive therapytr_TR
dc.subjectreactivation risktr_TR
dc.titleImmunosuppressive therapy and the risk of hepatitis B reactivation: Consensus reporttr_TR
dc.typeArticletr_TR

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
tjg-29-3-259.pdf
Size:
183.63 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.62 KB
Format:
Item-specific license agreed upon to submission
Description: